Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAX-001
- Development stage
- Unknown
- Lead developer
- Maxona Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MAX-001 is a proprietary, patent-protected oral formulation of nefopam developed by Maxona Pharmaceuticals. It is a non-opioid, non-NSAID analgesic designed for rapid onset and extended duration of pain relief. The drug acts as a triple neurotransmitter reuptake inhibitor with primary effects on norepinephrine (N), followed by serotonin (S), and dopamine (D) reuptake inhibition (N > S > D). This mechanism provides opioid-level efficacy for moderate to severe acute and chronic pain without the addiction risk or side effects associated with opioids or NSAIDs. Nefopam has been used internationally for over 40 years but is being newly formulated and clinically developed in the U.S. by Maxona Pharmaceuticals to address unmet needs in pain management[1][5][7].
- Brand names
- MAX-001MAX001MAX 001
- Other names
- nefopam (as the active molecule in the formulation)
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on MAX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAX-001.